TY - JOUR
T1 - High dose of liraglutide impairs renal function in female hypertensive rats
AU - Firmino, Felipe Tonon
AU - Peixoto, Pollyana
AU - Batista, Thatiany Jardim
AU - da Silva Escouto, Leonardo
AU - Brasil, Girlandia Alexandre
AU - dos Reis Couto, Mariana
AU - Ferreira de Melo, Antonio F.
AU - Bissoli, Nazaré Souza
N1 - Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc.
PY - 2025/2
Y1 - 2025/2
N2 - Glucagon-like peptide-1 (GLP-1) receptor agonists exhibit beneficial cardiovascular effects. However, the renal effects of different doses of liraglutide in an essential hypertension model have not yet been investigated. SHR female rats were treated for 30 days, twice a day, with saline (control) or liraglutide at low (0.06 mg/kg, LL) and high (0.6 mg/kg, LH) doses. Volume intake and excretion were monitored for a period of 24h. In renal tissue, nitrite-NO2-, nitrate-NO3-, advanced protein oxidation products-AOPP, collagen deposition, creatinine (Cr), urea (U), sodium, and potassium were analyzed. liraglutide reduced body weight gain in both groups. However, in the high dose, it increased urinary volume excretion and sodium/potassium ratio. Both doses reduced the urinary U/Cr ratio and LH increased the serum U/Cr ratio. AOPP was reduced only in LL. LH augmented collagen and early markers of kidney injury (blood urea nitrogen-BUN, BUN/Cr). LH increased NO3-, reduced NO2-, and caused an aberrant increase in GFR. Both doses’ effects were independent of blood pressure and glycemic control. liraglutide appears to have distinct effects on the hypertensive female kidney depending on the dose, with higher doses impairing kidney function.
AB - Glucagon-like peptide-1 (GLP-1) receptor agonists exhibit beneficial cardiovascular effects. However, the renal effects of different doses of liraglutide in an essential hypertension model have not yet been investigated. SHR female rats were treated for 30 days, twice a day, with saline (control) or liraglutide at low (0.06 mg/kg, LL) and high (0.6 mg/kg, LH) doses. Volume intake and excretion were monitored for a period of 24h. In renal tissue, nitrite-NO2-, nitrate-NO3-, advanced protein oxidation products-AOPP, collagen deposition, creatinine (Cr), urea (U), sodium, and potassium were analyzed. liraglutide reduced body weight gain in both groups. However, in the high dose, it increased urinary volume excretion and sodium/potassium ratio. Both doses reduced the urinary U/Cr ratio and LH increased the serum U/Cr ratio. AOPP was reduced only in LL. LH augmented collagen and early markers of kidney injury (blood urea nitrogen-BUN, BUN/Cr). LH increased NO3-, reduced NO2-, and caused an aberrant increase in GFR. Both doses’ effects were independent of blood pressure and glycemic control. liraglutide appears to have distinct effects on the hypertensive female kidney depending on the dose, with higher doses impairing kidney function.
KW - Blood urea nitrogen
KW - GLP-1
KW - Hypertension
KW - Kidney
KW - Liraglutide
UR - http://www.scopus.com/inward/record.url?scp=85209382601&partnerID=8YFLogxK
U2 - 10.1097/FJC.0000000000001649
DO - 10.1097/FJC.0000000000001649
M3 - Article
C2 - 39514188
AN - SCOPUS:85209382601
SN - 0160-2446
VL - 85
SP - 120
EP - 128
JO - Journal of cardiovascular pharmacology
JF - Journal of cardiovascular pharmacology
IS - 2
ER -